Histogen Inc. buy Ruckelsbuckel
Start price
15.07.22
/
60%
€3.06
Target price
15.07.23
€7.00
Performance (%)
-18.98%
End price
02.08.22
€2.48
Summary
This prediction ended on 02.08.22 with a price of €2.48. The prediction for Histogen Inc. disappointed with a performance of -18.98%. Ruckelsbuckel has 60% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Histogen Inc. | - | - | - |
| iShares Core DAX® | -0.315% | -2.776% | 12.361% |
| iShares Nasdaq 100 | 1.250% | 7.480% | 34.131% |
| iShares Nikkei 225® | -1.284% | -2.199% | 5.146% |
| iShares S&P 500 | 1.141% | 4.717% | 28.724% |
According to Ruckelsbuckel what are the pros and cons of Histogen Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Fair valuation
High Investments for future growth
ROE higher than 10% per year
Very capable Management
Good culture
Leading role in innovation
Some uniques
Differentiated customer and product portfolio
Growths faster than the competition
Stable Large shareholder and/or long term investor
Medium risks for its business
Top 10 in its market
Known brand
Very Future proof/growth oriented business model
Revenue growth >5% per year expected
Good rating
Cons
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Very low/no dividend yield expected
negative Cash Flow expected
Risky balance sheet
Increased challenges to pay loans and raise capital
Sustainability is little important
Significant cyclical dependencies